CPHI:NYE- (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 2

Change

-0.11 (-5.21)%

Market Cap

USD 7.24M

Volume

0.02M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-28 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+1.74 (+1.05%)

USD 72.38B
HLN Haleon plc

+0.08 (+0.71%)

USD 50.16B
TAK Takeda Pharmaceutical Co Ltd A..

+0.21 (+1.44%)

USD 44.08B
RDY Dr. Reddy’s Laboratories Ltd..

+0.19 (+1.30%)

USD 11.96B
ELAN Elanco Animal Health

+0.12 (+0.90%)

USD 6.42B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.09 (+1.25%)

USD 3.54B
BHC Bausch Health Companies Inc

+0.06 (+1.32%)

USD 1.73B
YCBD cbdMD Inc

+0.02 (+2.06%)

USD 8.19M
EVT Eaton Vance Tax Advantaged Div..

+0.33 (+1.44%)

N/A
TEVA Teva Pharma Industries Ltd ADR

-0.62 (-3.42%)

N/A

ETFs Containing CPHI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 760.22% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 760.22% 100% F 100% F
Trailing 12 Months  
Capital Gain 566.67% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 566.67% 100% F 100% F
Trailing 5 Years  
Capital Gain -91.11% 23% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.11% 23% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain 25.45% 87% B+ 88% B+
Dividend Return 25.45% 87% B+ 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 374.66% 13% F 3% F
Risk Adjusted Return 6.79% 47% F 28% F
Market Capitalization 7.24M 11% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector